We also know that some of the most important medical breakthroughs often result from collaborative R&D agreements and from partnerships. To find potential new therapies for patients we look both inside and outside AbbVie for promising discoveries. We partner and collaborate with peer companies, universities, non-governmental organisations, as well as other relevant groups, to help find solutions for patients around the globe—because we recognise there are times when we can accomplish more together than alone.
In early 2017, AbbVie announced a research partnership with Genuity Science (Ireland) to undertake a landmark population genomics alliance in Ireland. The 15-year project aims to sequence the genomes of 45,000 participants to identify novel targets and advance the clinical development of better treatments for a range of serious diseases. The collaboration will focus on key AbbVie therapeutic areas including oncology, neuroscience and immunology that affect hundreds of thousands of people in Ireland and hundreds of millions worldwide.
AbbVie is committed to research in Ireland. In 2015, a joint investment of €10 million by the Department of Jobs, Enterprise, and Innovation through Science Foundation Ireland (SFI) in a partnership with AbbVie was announced involving two new therapeutic research partnerships in Ireland. The collaborations, which will each investigate disease markers and potential targets against which new drugs may be developed, involve serious illnesses such as Crohn’s disease, rheumatoid arthritis, psoriasis and multiple sclerosis. Researchers at the SFI APC Microbiome Institute in University College Cork and at the Trinity Biomedical Sciences Institute in Trinity College Dublin are involved.